Skip to main content

Table 1 Baseline clinical and biochemical parameters of the study groups

From: Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial

Parameters Linagliptin Group
(n = 10)
Voglibose Group
(n = 9)
Control Group
(n = 7)
P-value
Age (years) 49.5 (41.5–55.5) 50.0 (45.0–54.0) 54.0 (48.5–59.5) 0.438
Sex (M:F) 5:5 7:2 5:2  
Duration of diabetes (years) 2.5 (1.0–3.0) 2.5 (0.8 to 3.0) 2.0 (0.8–2.8) 0.813
Weight (Kg) 75.3 (69.2–85.3) 60.7 (55.4–71.5) 74.0 (58.7–84.4) 0.071
BMI (Kg/m2) 25.5 (23.6–31.1) 25.9 (23.8–26.6) 26.4 (23.8–30.5) 0.834
HbA1c (%) 6.8 (6.4–7.1) 7.0 (6.8–7.4) 7.0 (6.8–7.1) 0.350
Fasting Plasma Glucose (mmol/L) 6.5 (5.9–7.3) 6.9 (6.2–7.4) 6.2 (6.1–6.6) 0.287
AUC C-peptide (nmol/L) 473.3 (376.9–567.8) 421.2 (40.9.8–526.9) 595.6 (460.5–623.8) 0.223
M0 × 10− 8 (1/min) −0.4(− 2.6–0.8) − 0.5 (− 2.8–1.2) −2.6(− 5.9–1.2) 0.834
M1 ×10−8 (1/min) 6.4 (4.5–8.7) 5.7 (3.6–7.6) 7.7 (5.5–10.6) 0.319
Glucose disposal rate (mg/Kg min) 2.7 (2.0–5.5) 3.2 (2.6–3.5) 2.2 (1.8–3.0) 0.297
Insulin sensitivity (mg/(Kgmin)/μU/mL) 4.4 (2.5–8.0) 5.3 (3.6–6.7) 3.2 (2.3–5.1) 0.315
HOMA-IR 2.0 (1.9–2.3) 1.6 (1.3–2.0) 1.9 (1.6–2.1) 0.261
HOMA-β (%) 84.1 (75.1–95.9) 65.0 (52.2–85.7) 92.5 (82.6–102.1) 0.067
  1. All values are expressed as median and interquartile range (1st IQR – 3rd IQR)
  2. AUC Area under curve, M0 Basal β-cell function, M1 postprandial β-cell function, HOMA-IR Homeostatic model assessment of insulin resistance, and HOMA-β Homeostatic model assessment of β cell function